Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’re sending the newsletter a bit early today since we’ve got some breaking news for you — plus a new FDA commissioner nominee. Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work. Continue…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. We’re sending the newsletter a bit early today since we’ve got some breaking news for you — plus a new FDA commissioner nominee.
Merck and Moderna’s mRNA cancer vaccine succeeds in late-stage trial
Scientists have long hoped that personalized mRNA cancer vaccines could be the next big breakthrough in oncology treatment. Today, Merck and Moderna said they had shown in a randomized late-stage trial for the first time that such a drug can work.
Continue to STAT+ to read the full story…
US Pharma Marketing